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n Abstract: Sentinel lymph node (SLN) biopsy is the standard procedure for axillary node staging in breast cancer.
Improvements in histopathological analysis and immunohistochemistry have recently increased the rate of detection of
lymph nodal micrometastases. The clinical implications and prognostic significance of micrometastases in SLN still remain
a controversial issue. Literature review was analyzed by searches of Medline and PubMed data bases. Whereas most stud-
ies carried on small groups of patients did not show differences in survival, recently some studies with longer follow-up and
with larger populations demonstrated that prognosis of patients with micrometastases is worse compared to that of patients
with SLN free of disease. To date, completion axillary dissection remains the standard option when a macro or micrometas-
tasis (0.2–2 mm) in the SLN is found. However, in absence of level-1 evidence guidelines, each case requires discussion in
the context of a multi-disciplinary team. n
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Axillary lymph node status represents the most sig-nificant prognostic factor in breast cancer. Senti-
nel node biopsy has been validated as the standard
technique in lymph nodal staging in breast cancer pre-
senting high accuracy and minimal morbidity.
The development in the anatomopathological tech-
niques of evaluation of sentinel lymph node (SLN)
with serial sectioning and immunohistochemistry
(ICH) has increased the identification rate of microm-
etastatic disease.
DEFINITION
Definition of micrometastasis is still controversial.
The V Edition of the American Joint Committee
(AJCC) Cancer Staging Manual defined ‘‘micrometas-
tasis’’ a single cluster of metastases till 2 mm of size.
The VI Edition of AJCC considered micrometastases a
single cluster of metastatic cells of 2.0 mm or less and
larger than 0.2 mm. Moreover, the same edition intro-
duced the term of ‘‘Isolated Tumor Cells’’ (ITC) to
consider single cells or small groups of cells of 0.2 mm
or less (1).
The prevalence of micrometastatic disease in SLN
ranges from 8% to 59% (mean 38%) (2).
DETECTION OF MICROMETASTASES
To date, most guidelines recommend a detailed anal-
ysis of SLN through multilevel sectioning coupled with
cytokeratin ICH (2). However, a recent review by
Cserni et al. (3) from about 240 pathology laboratories
in Europe revealed a great variability in the work-up of
nodes. On the basis of the survey by the European
Working Group for Breast Screening Pathology (3), the
most common methods, consisting of the evaluation of
six levels separated by 150 lm, were used by only eight
departments. A systematic and complete sampling is
carried out in 25% of cases. The distance between sec-
tions also shows great variability, ranging from 2 to
500 lm. The immunohistochemical technique is not
considered mandatory, but may be performed when the
hematoxylin and eosin-stained slides have suspicious
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cells that are equivocal. With the introduction of a
more detailed and intensive use of SLN, an upstaging
would be expected. In a recent review (3,4), the upstag-
ing rate ranged between 9% and 47% and upstaging
was seen to be enhanced by the use of ICH staining for
anticytokeratin. ICH seems to increase the ability of
detecting metastatic cells in lymph node tissue. In addi-
tion, in recent years, advances in molecular biology
have enabled highly sensitive techniques to be applied
to SLN analysis. Reverse transcriptase polymerase
chain reaction (RT-PCR) method is capable of detect-
ing trace amounts of keratin messenger RNA produced
by epithelial cells. RT-PCR has recently been reported
to reach a sensitivity of 89.5% and a specificity of
96.7% on frozen sections (5). RT-PCR is even more
sensitive than cytokeratin ICH and may identify very
low-volume nodal involvement but, on the contrary,
may also condition false signals. The VI AJCC Cancer
Staging system considers a pN0 (mol+) (sn) a SNL
found to be positive only by molecular methods (1).
PREDICTION OF NONSENTINEL LYMPH NODE
METASTASES
Prevalence of micrometastases in nonsentinel lymph
node in patients with sentinel node positive for
micrometastases ranges from 0% to 57%. Several
studies evidenced in multifactorial analysis that size of
metastases in SLN is the most powerful risk factor of
metastases in nonsentinel lymph nodes (6).
Viale and colleagues (7) published a study specific
addressing the risk of further axillary metastases in
patients with ITC-positive SLN. In this large single-
institution series, 1228 patients with positive SLN were
reclassified according to the VI AJCC Cancer Staging as
follows: 64.6% macrometastases, 26% micrometasta-
ses, and 9.4% ITC. Interestingly, further nonsentinel
metastases after axillary lymph node dissection (ALND)
have been found in 50.3%, 21.4%, and 14.4% of these
groups, respectively. Therefore, the finding of ITC in
SLN is associated with a small (14.4%) but not negligi-
ble risk of further axillary involvement, as well as mi-
crometastases of up to 1 mm in size (17%). If both
groups are considered together, patients with ITC only
or SLN metastasis smaller than 1 mm have the lowest
risk of additional metastases compared with those with
micrometastases 1–2 mm and those with SLN macrom-
etastases.
Of 2929 cases with breast carcinoma not larger
than 15 mm and staged with SLN biopsy, Cserni
et al. (8) found no further axillary involvement in the
other nodes dissected if the SLN had ITC (26 cases of
71 had ALND). In cases with micrometastases, 12%
had further axillary node involvement (178 cases of
234 cases had ALND). SLN macrometastases were
followed by axillary node involvement in 37% of
cases (299 of 335 cases had ALND). In a predictive
model considering the size of metastasis in the SLN
combined with other significant predictors (number of
positive SLNs and presence of vascular invasion of the
primary tumor), patients with the most favorable
combination of predictive factors still have a 13% risk
of developing nonsentinel node metastases. So, even if
most surgeons would not recommend completion axil-
lary dissection in ITC-positive SLN, in others’ opin-
ions, it should be offered outside clinical trials.
PROGNOSTIC IMPLICATIONS OF
MICROMETASTATIC DISEASE
Despite intensive working on the prognostic signifi-
cance of micrometastases and ITC in the SLN, their
clinical implications remain unknown.
Whereas the first studies on small groups of
patients did not evidence differences in survival,
recently several studies with longer follow-up
(4–25 years) and with larger populations demon-
strated that prognosis of patients with micrometasta-
ses is quite different from patients with SLN free of
disease. The International Breast Cancer Study Group
on 921 patients evidenced an increased risk of local
recurrence in patients with micrometastases (9). The
study of Grabau et al. (10), to date that with the larg-
est population, has demonstrated a significantly worse
overall survival in patients with micrometastases (RR
1.20, 95% CI, p = 0.04) compared with node-negative
patients. Similar results have been reported by Colle-
oni (11) and Kujit (12). Chen et al. (13) reported
SEER data of 209720 cases among which, in multivar-
iate analysis of overall survival, cases with microme-
tastases had a HR of 1.35 compared with node-
negative patients and of 0.82 compared with cases
with macrometastases.
PRACTICAL APPROACH TO MICROMETASTATIC
DISEASE
It is still a controversial issue what is the best pro-
cedure to perform in case of micrometastatic disease
in SLN. In approximately 80% of patients with SLN
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micrometastases, the SLN is the only involved axillary
lymph node; therefore, further axillary surgery may be
considered an overtreatment. The guidelines of the
American Society of Clinical Oncology (ASCO) (14)
recommend ALND in patients with micrometastases
in SLN. To date, completion axillary dissection
remains the standard option when a macrometastasis
or micrometastasis (0.2–2 mm) in the SLN is found,
while in the case of detection of ITC-positive
SLN axillary dissection may be omitted, even if the
low risk of further axillary involvement should be
considered.
ONGOING RANDOMISED CLINICAL TRIALS
In the few next years, the ongoing large randomised
trials will issue their preliminary results, both in Eur-
ope (Trial 23-01 of the International Breast Cancer
StudyGroup [IBCSG]) and the USA (the ACOGSOG
study Z0010 and NSABP study B-32). Results from
these trials are expected to give an important contri-
bution to clarify the prognostic value of micrometa-
stasis and ITCs in SLN and whether sparing an
axillary dissection in micrometastatic SLN is safe.
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